CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Show more
Location: 1111 Main Street, Vancouver, WA, 98660, United States | Website: https://www.cytodyn.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
394.4M
52 Wk Range
$0.10 - $0.49
Previous Close
$0.32
Open
$0.30
Volume
1,059,527
Day Range
$0.30 - $0.33
Enterprise Value
346.8M
Cash
16.4M
Avg Qtr Burn
-1.188M
Insider Ownership
0.55%
Institutional Own.
0.02%
Qtr Updated
02/28/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Leronlimab Details Non-alcoholic steatohepatitis | Phase 2/3 Update | |
Leronlimab in comb w/trifluridine+ tipiracil (TAS-102)+ bevacizumab Details Metastatic colorectal cancer | Phase 2 Data readout | |
Leronlimab Details Human immunodeficiency virus | Phase 2 Update | |
Leronlimab Details Solid tumor/s, Cancer | Phase 2 Update | |
Leronlimab Details Graft-versus-host disease | Failed Discontinued | |
Leronlimab Details COVID-19 | Failed Discontinued |